Research programme: anti-infective monoclonal antibodies - Kling Biotherapeutics
Alternative Names: Anti Staph A mAb rF1; Bispecific influenza virus antibody; Clostridium difficile antibody; Cytomegalovirus antibody; Hepatitis C virus antibody; Parechovirus antibody; rF1Latest Information Update: 28 Dec 2021
Price :
$50 *
At a glance
- Originator AIMM Therapeutics
- Developer Genentech; Kling Biotherapeutics
- Class Monoclonal antibodies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Picornavirus infections
Highest Development Phases
- No development reported Cytomegalovirus infections; Hepatitis C; Methicillin-resistant Staphylococcus aureus infections; Picornavirus infections
- Discontinued Clostridium difficile infections
Most Recent Events
- 28 Dec 2021 No recent reports of development identified for preclinical development in Methicillin-resistant-Staphylococcus-aureus-infections in Netherlands (Parenteral)
- 25 Jan 2018 Preclinical development for Methicillin-resistant Staphylococcus aureus infections is ongoing (AIMM Therapeutics pipeline, January 2018)
- 25 Jan 2018 Discontinued for Clostridium difficile infections in Netherlands (Parenteral)